African Horse Sickness Virus

Overview and Taxonomy of African Horse Sickness Virus

African horse sickness virus (AHSV) is an arthropod-borne virus that has garnered significant attention due to its devastating impact on equids across sub‐Saharan Africa and its potential to cause major outbreaks in non‐endemic regions. Classified within the genus Orbivirus in the family Sedoreoviridae, AHSV is a double‐stranded RNA virus characterized by a segmented genome and an intricate capsid structure that is central to its biology and pathogenicity [6]. The virus presents as one of the economically critical pathogens recognized by global animal health authorities such as the World Organisation for Animal Health (WOAH), the World Health Organization (WHO), and the Food and Agriculture Organization (FAO), underscoring its importance not only to veterinary practice but also to international trade and equine health management.

At the molecular level, AHSV’s genome is comprised of 10 linear segments of double‐stranded RNA, arranged in a decreasing order of size (Seg-1 to Seg-10). These segments encode both structural and non-structural proteins that are instrumental in the virus’s replication cycle, virulence, and immune evasion strategies [4, 6]. Among the proteins, the outer capsid protein VP2 is the most variable antigen and defines the nine distinct serotypes of the virus, with limited cross-protection between serotypes [1, 4, 6]. In contrast, the highly conserved VP7 is a group-specific antigen; its conservation among different serotypes makes it an ideal target for serological assays and vaccine design, as seen in studies that have mapped B-cell epitopes and evaluated its potential in both recombinant vaccine formulations and diagnostic platforms [2, 3, 7]. This molecular dichotomy between highly divergent VP2 and conserved internal proteins such as VP7 encapsulates the challenges and opportunities in both the epidemiological surveillance and the development of next-generation AHSV vaccines.

Structurally, the AHSV particle is built from several concentric layers. The innermost layer, primarily made up of VP3, houses the transcriptional complex that includes viral polymerase proteins and other enzymes necessary for genome replication [10]. Surrounding this is the middle layer composed largely of VP7, which not only contributes to the core’s stability but also mediates interactions with host cells and insect vectors [2, 10]. The outer capsid, consisting mainly of VP2 and VP5, plays a critical role in host cell receptor binding, virus entry, and determining the serotype-specific immune response. The precise interplay among these proteins not only defines the virus’s host range and tissue tropism but also influences its ability to circumvent host defenses. This compartmentalization of functions within the virion structure reinforces the complexity of AHSV's biological mechanisms and the mechanistic basis for its high virulence in susceptible equine populations [6, 10].

Epidemiologically, AHSV is predominantly transmitted by certain species of Culicoides biting midges. These vectors facilitate rapid dissemination of the virus during favorable environmental conditions, thus explaining the seasonal nature and the occasional explosive outbreaks of African horse sickness (AHS) in endemic regions as well as the sporadic incursions into previously unaffected areas like parts of Europe and Asia [5, 6]. The global spread of vector-borne diseases is monitored and regulated by international bodies such as the CDC and WOAH, with stringent guidelines developed to prevent and control outbreaks. The high mortality rates in naïve populations, often exceeding 90% in susceptible horses, combined with the virus’s potential for rapid geographic spread via its vectors, contribute to AHSV’s reputation as a pathogen of significant economic and animal health concern [6].

Taxonomically, the orbiviruses exhibit a significant amount of genetic diversity, with AHSV standing out due to its nine well-characterized serotypes [1, 4, 6]. This diversity is primarily a result of the variability in the VP2 gene, which is subject to both mutation and reassortment events. In fact, reassortment between different serotypes has been documented, posing additional challenges for vaccine design and serological assays as novel virus variants can emerge that evade existing immunity. Furthermore, studies have provided evidence that intragenic recombination, although less common, may also contribute to the genetic variability observed in AHSV [8]. Such processes underpin the dynamic evolutionary landscape of the virus and necessitate continuous monitoring and periodic updates to diagnostic protocols and vaccine formulations [4, 6].

Beyond the immediate implications for disease spread, the taxonomic classification of AHSV has practical relevance for veterinary immunology and the development of countermeasures. Research leveraging reverse genetics has enabled the generation of reassortant and replication-incompetent virus particles that serve both as models for studying virus assembly and as promising candidates for vaccines that can provide cross-serotype protection [10, 12, 13]. These innovative approaches, partly inspired by techniques applied to other orbiviruses such as bluetongue virus, illustrate the potential for using AHSV’s molecular architecture as a blueprint for rational vaccine design [9, 11]. The evolutionary relationships within the Orbivirus genus are continually refined as whole-genome sequencing and advanced bioinformatics tools contribute to a clearer picture of the virus’s phylogeny and its divergence from related pathogens [14].

In summary, African horse sickness virus is an orbivirus of significant veterinary importance whose detailed taxonomic characterization informs not only its diagnostic and epidemiological management but also the strategic development of safe and effective vaccines. Its segmented, double-stranded RNA genome, variable outer capsid proteins, and conserved inner core proteins jointly constitute a paradigm of viral complexity that poses both challenges and opportunities for modern veterinary virology, a perspective echoed in the extensive body of contemporary research on this pathogen [1, 4, 6, 8].

Molecular Structure of African Horse Sickness Virus

African horse sickness virus (AHSV) is a member of the genus Orbivirus within the Sedoreoviridae family, characterized by a complex, multilayered structure built around a segmented double-stranded RNA (dsRNA) genome [6]. The virion is composed of a total of ten linear genomic segments arranged in decreasing order of size (Seg-1 to Seg-10). These segments encode seven structural proteins and several non-structural proteins that are critical for viral replication, assembly, and pathogenesis. The outer capsid is predominantly formed by the proteins VP2 and VP5, whereas the inner capsid (or core) comprises proteins VP7 and VP3, encasing the genome and the viral polymerase complexes [10].

VP2, the most outwardly exposed protein, plays a central role as the serotype-determining antigen and is responsible for the induction of neutralizing antibodies [4]. This protein is highly variable across the nine recognized serotypes of AHSV, and its hypervariability is a critical determinant of antigenicity and host immune recognition. Molecular studies have revealed that specific amino acid substitutions and unique motifs in VP2 contribute not only to serotype specificity but may also impact receptor binding and efficiency of tissue cell entry, making VP2 a target of intense investigation for vaccine development and diagnostic assays [15, 17]. The comparative analysis of VP2 genetic sequences from various AHSV isolates has further established that nucleotide and amino acid changes correlate with differential pathogenic profiles. For instance, VP2 exchanges have been exploited in designing disabled infectious single animal (DISA) vaccine candidates by swapping serotype-specific segments, which in turn modulate both immune responses and virus release kinetics [12].

Encapsulated within the VP2/VP5 shell lies the core of the virus, consisting of the highly conserved proteins VP7 and VP3. VP7, in particular, assembles as trimers to form the structural framework of the core particle [19]. One intriguing molecular characteristic of AHSV is the intrinsic propensity of VP7 to form crystalline aggregates in infected cells, a feature that appears to be unique to this orbivirus compared to others such as bluetongue virus. Studies using site-directed mutagenesis demonstrated that substitution of specific amino acids in VP7 can disrupt its self-assembly into crystals, facilitating the production of soluble forms that retain the ability to interact with VP3, a finding that has significant implications for recombinant vaccine development [18, 19]. The conserved nature of VP7 across different serotypes also underscores its utility as a diagnostic antigen in serological assays, as demonstrated by its inclusion in multiplex immunoassays that target conserved epitopes of AHSV for broad-spectrum detection [3, 27].

Additionally, AHSV’s inner layers harbor the minor structural proteins VP1, VP4, and VP6, which together form the replicase complex necessary for transcription and replication of the segmented genome. Although these proteins are less exposed to the host’s immune system, their conservation across serotypes indicates essential functions in the viral life cycle. The coordinated assembly of these proteins results in a highly ordered and efficient machinery that enables the robust replication of AHSV within host cells [10].

Non-structural proteins such as NS1, NS2, NS3/NS3a, and the more recently described NS4 further add to the complexity of the molecular architecture of AHSV. NS3/NS3a, for example, has been implicated in virus release and cytopathic effects in infected mammalian cells, and its deletion or mutation has been harnessed to produce replication-abortive vaccine strains [12, 23]. Meanwhile, NS4, a nucleocytoplasmic protein encoded by an alternative reading frame of Seg-9, binds double-stranded DNA and is thought to modulate the host cell’s immune responses, although its precise roles continue to be elucidated [25]. These accessory proteins are critical in shaping the interaction of the virus with host cellular pathways, as they can interfere with pivotal signaling cascades such as the JAK-STAT pathway, thereby allowing the virus to overcome innate immune defenses [23, 24].

Genetic Variability of African Horse Sickness Virus

The genetic variability of AHSV is primarily described by the differences in its outer capsid protein VP2, which distinguishes the nine serotypes circulating globally. The natural evolution of AHSV occurs through a combination of point mutations within individual segments and segment reassortment during co-infections. Reassortment events have been documented between field isolates and even between vaccine strains and field viruses, contributing to a complex genetic landscape [1, 8]. Such genetic reassortment is notable because it can lead to the generation of novel virus variants with distinct antigenic profiles and altered virulence characteristics. Detailed whole-genome sequencing analyses have confirmed over 95% homology in the major antigenic proteins among certain AHSV isolates, yet even minor genetic differences in VP2 can drastically affect the efficacy of current vaccines and diagnostic assays [1, 20].

Beyond VP2, variability is also observed in other structural and non-structural proteins, albeit to a lesser extent. For example, the modifications in VP7, albeit conserved in its core assembly function, may alter its crystallization behavior, a factor that influences not only viral pathogenesis but also vaccine formulation strategies [18, 19]. The stability and integrity of the core structure, owing much to the sequence conservation in VP7 and VP3, facilitate a reliable framework for the replication complex, yet they do not completely preclude minor variations that may arise during viral replication and adaptation to new hosts or vectors [10, 14].

Furthermore, the non-structural proteins exhibit genetic variability that ensures the virus maintains an adaptive balance between replication efficiency and immune evasion. The NS3/NS3a proteins in particular have been the focus of studies that reveal how targeted deletions or mutations can attenuate virulence while preserving immunogenicity. Through reverse genetics techniques, directed mutational analyses have illuminated the role of various protein domains in determining host cell interactions, virus release, and overall pathogenicity [23, 26]. These insights are particularly crucial when considering the global spread of AHSV during outbreaks, as noted by the World Organisation for Animal Health (WOAH) and relevant international agencies such as the CDC and FAO, which stress the importance of molecular surveillance for emerging or re-emerging strains of this economically significant pathogen.

The cumulative effect of these genetic changes underscores the challenges in controlling AHSV through vaccination and argues for the continuous monitoring of viral evolution. Diagnostic assays, particularly those based on molecular detection of conserved regions, such as the Seg-7 gene targeted by RT-MIRA, are adapted regularly to account for sequence heterogeneity in emerging variants [16, 22]. This genetic plasticity necessitates an integrated approach to vaccine design, wherein recombinant vaccines based on conserved components may be complemented by strategies that specifically target the variable VP2 to achieve serotype-specific protection [15, 21].

In summary, the molecular structure and genetic variability of AHSV play a central role in both its pathogenesis and the development of control strategies. Detailed understanding of the structural organization, from the outer capsid proteins determining serotype specificity to the inner core proteins essential for replication, coupled with insights into the genetic dynamics driving variation, remain at the forefront of research initiatives aimed at improving diagnostics, vaccines, and epidemiological surveillance of this economically critical virus.

Molecular Pathogenesis of African Horse Sickness Virus

African horse sickness virus (AHSV) is a unique arbovirus belonging to the genus Orbivirus within the family Sedoreoviridae. Its molecular pathogenesis results from a complex interplay between its multilayered virion structure, numerous viral proteins that mediate host cell entry and replication, and the capacity to subvert host immune responses. The virus’s segmented double-stranded RNA genome encodes both structural proteins, such as VP2 and VP7, and non-structural proteins (e.g., NS3, NS4) that together orchestrate its virulence and highly lethal disease course in equine species [6, 34].

Viral Structure, Genome, and Protein Functions

AHSV’s genome is composed of ten segments of double-stranded RNA, each encoding a different protein. Among these, the outer-capsid protein VP2 is both the most variable and the primary determinant of serotype and antigenicity. VP2 not only elicits neutralizing antibodies but also plays a crucial role during the early stages of infection by mediating viral attachment and cell entry [1, 2]. In contrast, the inner-core proteins, including VP7, are more conserved and are essential for the formation of the viral core. Unlike other orbiviruses, AHSV’s VP7 has an unusual propensity to form crystalline aggregates in infected cells. Although these aggregates were long thought to be mere by-products of viral protein expression, recent studies indicate that VP7 aggregation is intricately associated with virus assembly and may also influence cell-to-cell spread and immune evasion [2, 18, 19]. Furthermore, the role of VP2 and VP7 in the viral life cycle extends into vector interactions, as modifications of these proteins affect binding to Culicoides-derived cells, a critical factor for transmission [2].

The non-structural proteins of AHSV are central to modulating host responses. NS3, for example, is implicated in the final stages of virus egress and can influence the efficiency of virus release from infected cells [12, 26]. However, increasing attention has been directed at NS4, a protein encoded from an alternative reading frame of the genome segment that also harbors VP6. NS4 has been shown to display nucleocytoplasmic localization and to bind double-stranded DNA. It exerts its effect by delaying the activation of key immune signaling pathways, most notably the JAK-STAT pathway, which leads to a suppression of the host antiviral response [23, 32]. This interference with interferon responses provides the virus with a critical window to replicate undetected in the early phases of infection.

Molecular Mechanisms of Immune Evasion

The capacity of AHSV to interfere with host innate immune pathways is one of the hallmarks of its molecular pathogenesis. Evidence from studies employing IFNAR (Interferon-α/β receptor) knockout mouse models, which mimic key aspects of AHSV infection in horses, reveals that the viral modulation of cytokine expression is extensive. In these models, an initial subdued type I and type III interferon response is followed by an aberrant upregulation of pro-inflammatory cytokines and chemokines, disrupting the normal balance of immune homeostasis in target organs such as the spleen, liver, and brain [28, 31]. NS4, by delaying the nuclear translocation and phosphorylation of STAT1, effectively dampens the antiviral state that would normally restrict viral replication. This immune subversion strategy is complemented by the actions of NS3, which, when deleted, leads to an attenuated phenotype, underscoring its role in facilitating efficient viral spread [23, 24].

Moreover, transcriptome analyses of peripheral blood mononuclear cells (PBMCs) infected in vitro with virulent strains of AHSV indicate that the virus impairs the upstream signaling cascades that would otherwise trigger robust expression of antiviral interferons [32, 33]. In some instances, this suppression results in prolonged survival of infected cells, creating a reservoir wherein viral replication can continue with reduced immune clearance. Conversely, in other cell populations, the virus can induce apoptosis via intrinsic and extrinsic pathways. This dichotomy, cell death in some contexts and immune evasion in others, highlights the sophisticated molecular tactics employed by AHSV to navigate host defenses [33].

Viral Replication and Host Cell Interaction

Following receptor-mediated endocytosis, AHSV uncoats in the cytoplasm, releasing its segmented dsRNA into a protected environment within viral cores. The viral RNA-dependent RNA polymerase (VP1) then transcribes mRNAs from each genome segment inside these cores, thereby sheltering the viral replication process from cytosolic pattern recognition receptors (PRRs) [6, 34]. Despite these protective measures, some viral RNA escapes into the cytosol, where it may be recognized by PRRs such as RIG-I and MDA5. In response, infected cells usually mount an antiviral response; however, AHSV’s non-structural proteins effectively counteract this threat. For instance, the early expression of NS4 and NS3 not only modulates the levels of interferon production but also affects downstream signaling to ensure that the virus can complete its replication cycle without triggering a robust antiviral state [23, 32].

Another intriguing aspect of AHSV pathogenesis is its modulation of host cell machinery. The crystalline aggregates of VP7, a phenomenon that is relatively unique among orbiviruses, may play a dual role, not only in viral assembly but also in sequestering cellular factors that might otherwise facilitate antiviral responses [18, 19]. This sequestration could serve as a decoy mechanism, distracting cellular defenses from the active replication complexes. Meanwhile, the interactions of VP2 with host cell receptors, while essential for initiating infection, also appear to be finely tuned to avoid immediate recognition by the host immune surveillance systems, which is critical given the high mortality observed in naïve equine hosts [1, 15].

Host Tropism and Impact on Disease Outcome

Differences in the pathogenic outcomes among various hosts can, in part, be ascribed to the molecular mechanisms described above. In horses, which are highly susceptible to AHSV, the combination of rapid viral replication, effective immune suppression via NS4 (and accessory roles played by other non-structural proteins), and the complex interplay of pro-inflammatory and anti-inflammatory cytokines leads to a rapid and severe disease course [29, 30]. The high mortality in naïve populations is reflective of an insufficient or misdirected immune response, exacerbated by the virus’s ability to delay interferon responses and reprogram host transcriptional pathways [23, 32]. In contrast, species such as zebras and donkeys exhibit milder pathological responses. Although the molecular determinants for these differences are still under investigation, variations in the innate immune responses of different equid species may modulate the effectiveness of the viral immune evasion strategies [6, 34].

These pathogenic mechanisms have significant implications for disease surveillance and control, as recognized by international organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO). Enhanced molecular diagnostic approaches, including advanced real-time PCR assays, capitalizing on our understanding of the viral genome and its conserved regions, are now critical to provide rapid and sensitive detection during potential outbreaks [16, 22]. Moreover, these insights have spurred developments in vaccine design, especially next-generation vaccines that avoid the drawbacks of live-attenuated strains, by targeting specific viral proteins critical for virulence and immune evasion, such as VP2 and NS4 [9, 15].

Collectively, the molecular pathogenesis of AHSV is a multifaceted process involving a precisely orchestrated interplay between viral structural and non-structural proteins and the host immune system, which ultimately culminates in the severe clinical outcomes observed in highly susceptible equid populations [23, 32, 33].

Epidemiology and Global Distribution of African Horse Sickness Virus

African horse sickness virus (AHSV) is a vector-borne orbivirus that remains a significant threat to equine populations, particularly in sub-Saharan Africa, where the disease is endemic. The epidemiological dynamics of AHSV are strongly influenced by complex interactions between virus, vector, host, and environmental factors. Viral spread is primarily mediated by Culicoides biting midges, whose abundance and distribution are affected by climatic conditions, geographic features, and seasonal variations, thereby dictating the spatial and temporal transmission patterns of AHSV [6, 41].

Endemicity in Sub-Saharan Africa and Regional Outbreak Patterns

AHSV has been reported as highly endemic in sub-Saharan Africa, where climatic patterns and the presence of competent Culicoides vectors create ideal conditions for persistent circulation among equids [6]. Historically, equine populations in Africa have experienced repeated AHSV outbreaks, with the virus causing high mortality amongst naive domestic horses while often producing milder symptoms in indigenous species such as zebras and donkeys [34]. In countries like Nigeria, studies have revealed very high seroprevalence rates in horses, suggesting widespread exposure to AHSV. For instance, seroprevalence surveys have demonstrated antibody-positive rates exceeding 80% in equine populations, highlighting the virus's persistence and the continuous exposure risk posed by the vector populations [35]. These findings are corroborated by rigorous surveillance data from various African regions, which indicate that environmental determinants such as rainfall, temperature, and altitude are integral to the virus’s transmission dynamics [36, 44].

Spread Beyond Endemic Regions

While Africa is traditionally considered the epicenter of AHSV, the virus has breached its endemic boundaries on several occasions. Outbreaks in temperate regions of Europe and parts of Southeast Asia have been documented, reflecting the potential for viral incursion beyond traditional confines. A historical understanding of patterns reveals that outbreaks outside Africa, such as those in Morocco in the late 1980s and early 1990s, resulted from the virus’s ability to exploit both vector migration and anthropogenic movements, including the legal and illegal trade of equids [38, 40]. In these cases, the spatio-temporal models have shown that even limited vector dispersal can lead to significant disease emergence in previously naive regions. The ecological niche models, which incorporate parameters like solar radiation, altitude, and precipitation seasonality, predict that environmental suitability for AHSV is not restricted solely to Africa. Crucial areas in South Asia, parts of South America, and Australia have been identified as having high environmental suitability for the virus, underscoring the importance of global surveillance and robust biosecurity measures [36, 45].

Vector Ecology and Climate Influences

Central to the epidemiology of AHSV is the biology of Culicoides midges, which act as the primary vectors for the virus. Studies in Europe and Africa have demonstrated that not all Culicoides species are equally effective vectors. For example, research in the Niayes region of Senegal has identified species such as Culicoides oxystoma and C. imicola as having high vectorial capacity, primarily due to their strong host-feeding behavior on equids [43]. In contrast, studies in the pre-alpine regions of Switzerland have found that while some species may harbor viral RNA, the vector competence is likely lower due to environmental constraints that reduce midge abundance and activity [5]. These differences underscore the role of climatic and ecological factors in shaping the global distribution of AHSV, where warmer climates and specific ecological niches support higher vector densities and more efficient viral transmission.

The influence of climate is also evident from ecological niche modeling efforts. Variables such as mean maximum temperature and average annual precipitation have been shown to significantly shape the habitats suitable for AHSV transmission. These models predict that under future climate change scenarios extending to 2060, the potential distribution of AHSV could expand into new areas, thus raising concerns from international animal health authorities such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) [36]. In addition, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) underscore the importance of robust vector surveillance and environmental monitoring to preempt and manage potential outbreaks in non-endemic regions.

Cross-Species Transmission and Role of Secondary Hosts

Though AHSV is primarily an equine pathogen, recent studies have expanded the understanding of its host range and possible transmission dynamics in secondary hosts. There are reports of serological evidence in domestic dogs, species which historically had been considered incidental or dead-end hosts after ingesting contaminated horse meat. However, seroconversion rates in dogs and experimental studies now suggest that dogs might be more frequently exposed to the virus through midge-borne transmission than previously thought [37, 42]. In equine species, the variability in clinical outcomes, ranging from severe disease in horses to subclinical infections in zebras and donkeys, points to a complex interplay between host immune responses and viral factors, which may ultimately influence regional virus persistence and spread [34].

Human-mediated Factors and International Spread

Anthropogenic factors also play a crucial role in the epidemiology of AHSV. The legal movement and trade of equids have been identified as a significant risk for the international introduction of the virus into previously AHSV-free zones [40]. Countries with high equine densities and frequent international movement may inadvertently provide corridors for viral transmission, particularly in the context of suboptimal vaccination and biosecurity practices. Enhanced molecular surveillance using advanced diagnostics, such as multiplex real-time RT-PCR assays, further highlights the importance of rapid detection and serotype-specific characterization, which are essential for prompt disease control interventions [4, 39]. Consequently, international collaborations coordinated by agencies such as WOAH, WHO, and the CDC continue to strengthen global preparedness by developing comprehensive surveillance systems and vaccination policies tailored to the evolving epidemiological landscape.

The Role of Mathematical and Ecological Modeling

Mathematical models have further enriched the understanding of AHSV transmission dynamics. Spatio-temporal models incorporating infection kernels and movement data have been successful in estimating transmission rates over various geographic scales, from village-level transmission up to regional outbreaks [38]. When combined with ecological niche modeling, these approaches provide a framework for predicting potential future outbreaks and for guiding targeted surveillance. Such multi-faceted models have proven invaluable in designing risk-based surveillance strategies, especially in areas where equine industries are economically significant and where introduction of AHSV could have devastating trade implications [36, 38, 46]. These integrated models are referenced by authorities such as the WOAH in their disease control protocols, further emphasizing the global significance of targeted epidemiological investigations.

By comprehensively integrating field surveillance data, vector ecology insights, and advanced mathematical modeling, the epidemiology and global distribution of AHSV are understood as a dynamic and multifactorial phenomenon. This integrated approach is essential for preventing future outbreaks and for ensuring effective international collaboration, as underscored by global health agencies such as the CDC, WHO, and WOAH.

Diagnostic Modalities and Surveillance Strategies for African Horse Sickness Virus

African horse sickness virus (AHSV), a lethal orbivirus transmitted by Culicoides biting midges, necessitates rapid and sensitive diagnostic methods and robust surveillance systems due to its devastating impact on equine populations. Given the high economic and animal health burden as outlined by international organizations such as the World Organisation for Animal Health (WOAH) and exemplified by guidelines from the CDC and WHO, multiple diagnostic platforms and surveillance strategies have been developed to monitor and control AHSV outbreaks.

Nucleic Acid-Based Diagnostic Modalities

The cornerstone of modern diagnosis for AHSV relies on nucleic acid amplification techniques that target conserved viral genome segments. Real-time reverse transcription polymerase chain reaction (RT-qPCR) remains a widely accepted method, yet inherent challenges such as sequence variability and the need for sophisticated laboratory equipment have driven the development of alternative methodologies. For instance, modified RT-qPCR assays incorporating degenerate primer and probe sets have been successfully implemented to detect new virus variants, thereby overcoming issues of mispriming due to genetic drift in the VP7 and VP2 gene regions [22, 47]. This molecular diagnostic evolution is critical, especially under WOAH-recommended protocols, which emphasize rapid detection in outbreak scenarios.

In addition to conventional RT-qPCR, the implementation of innovative isothermal amplification methods has gained traction. The real-time reverse transcription multienzyme isothermal rapid amplification (RT-MIRA) assay has demonstrated diagnostic sensitivity comparable to RT-qPCR, with the added advantage of operational simplicity that allows its application in remote or field settings [16]. This method enables the rapid amplification of target nucleic acids under isothermal conditions, making it particularly useful during border inspections or in outbreak areas where access to high-end laboratory infrastructure is uncertain.

Another promising approach is the use of multiplex PCR in combination with microsphere-based xMAP technology. Such assays simultaneously differentiate all nine AHSV serotypes within a single run, thereby reducing turnaround time and optimizing resource use in outbreak investigations [4, 50]. By targeting serotype-specific genome segments, these multiplex systems not only facilitate diagnosis but also contribute to vaccine selection and the epidemiological tracing of virus incursions.

Short of laboratory-based techniques, diagnostic sensitivity can be maintained during sample transport and storage by utilizing Flinders Technology Associates (FTA) cards. These cards have proven to stabilize viral RNA, allowing subsequent recovery and amplification through conventional and isothermal RT-PCR methods [48, 51]. Their integration into sample collection protocols enhances biosecurity, as they rapidly inactivate infectious agents, and supports the establishment of reliable epidemiological baselines during surveillance activities.

Serological and Immunological Assays

Serological testing plays a complementary role in AHSV detection, particularly for monitoring immune responses following vaccination or natural infection. Competitive enzyme-linked immunosorbent assays (cELISA) and indirect ELISAs have been employed to detect antibodies specific to conserved structural proteins such as VP7 [3, 27, 35]. The identification of linear B-cell epitopes on VP7 further refines serodiagnostic precision, assisting in differentiating between exposure due to vaccination versus natural infection. Given the persistent challenges in differentiating infected from vaccinated animals (DIVA), especially in regions with live attenuated vaccine usage [39], the implementation of serotype-specific serological assays remains an active area of diagnostic research.

Advanced immunoassay platforms, such as microsphere-based immunoassays, offer increased sensitivity and throughput. By using recombinant AHSV proteins as antigenic baits, these systems can simultaneously screen for antibodies against multiple virus antigens in a single sample, thereby expediting large-scale serosurveillance programs [27]. Such assays are instrumental when deployed in endemic regions where high seroprevalence rates necessitate rapid discrimination of infection trends within diverse equine populations.

Surveillance Strategies and Epidemiological Modeling

Surveillance strategies for AHSV hinge on the integration of advanced diagnostic methodologies with epidemiological tools to monitor virus circulation and assess outbreak risks on regional and international scales. The vector-borne nature of AHSV emphasizes the necessity for arthropod surveillance, particularly in identifying and mapping populations of Culicoides midges known to serve as transmission vehicles. Studies examining the vector competence and feeding behaviors of these midges in different ecological niches have provided critical insights into likely pathways of viral incursion and have guided targeted control measures [5, 49].

Recent ecological niche modeling approaches have further refined surveillance by predicting the potential distribution of AHSV based on environmental parameters such as solar radiation, temperature extremes, precipitation patterns, and altitude [36, 45]. Models employing ensemble techniques have accurately delineated high-risk areas, for example within sub-Saharan Africa and regions considered susceptible due to favorable climatic conditions, such as parts of Southern Europe and Latin America [36, 46]. These models are essential components of risk-based surveillance systems, enabling veterinary authorities to preemptively allocate resources and implement control measures in predicted hotspots.

Risk-based surveillance is also underpinned by spatial-temporal epidemiological models that integrate historical outbreak data with current surveillance indicators. These models utilize transmission kernels that describe how virus transmissibility attenuates with increasing distance between infected premises, thereby informing targeted testing and movement control strategies [38]. Such data-driven approaches are increasingly relied upon by international bodies like WOAH and FAO, which guide member states in developing early warning systems and response strategies to manage potential AHSV outbreaks.

Integrating both active and passive surveillance data is crucial. Active surveillance involves the systematic screening of equine populations through periodic diagnostic testing using RT-qPCR and serological assays. In contrast, passive surveillance, which relies on the reporting of suspected clinical cases, is bolstered by awareness campaigns and training provided by international organizations such as the CDC and WOAH. These initiatives ensure that veterinary personnel in both endemic and non-endemic regions are equipped to detect early signs of AHSV infection and can rapidly deploy molecular and serological diagnostic tools to contain any outbreak.

In summary, the diagnostic landscape for AHSV is marked by a suite of sophisticated nucleic acid and serological assays that collectively enable rapid, sensitive, and serotype-specific detection of the virus [4, 16, 39, 47, 51]. Coupled with advanced surveillance strategies and predictive ecological modeling, these tools form an integrated framework essential for monitoring the dynamic epidemiology of AHSV and mitigating its impact on equine populations globally.

Advances in Vaccine Development and Immunogenicity Evaluations for African Horse Sickness Virus

Recent progress in the development of vaccines against African horse sickness virus (AHSV) has leveraged a complex interplay of novel vaccine platforms, reverse genetics strategies, and tailored immunogenicity evaluations. Given the catastrophic economic and animal health implications underscored by outbreaks reported by international organizations such as the WOAH and FAO, modern vaccine designs are focusing on improved biosafety, cross-serotype protection, and DIVA (differentiating infected from vaccinated animals) compatibility to meet the stringent requirements required by regulatory bodies and trade partners worldwide.

Emergence of Novel Vaccine Platforms and Molecular Approaches

One of the significant breakthroughs in AHSV vaccine development has been the generation of recombinant vaccine candidates capable of inducing robust protective immune responses without the safety concerns associated with traditional live attenuated vaccines. For instance, the construction of a recombinant fowlpox virus expressing the VP2 antigen of AHSV serotype 1 has demonstrated a promising immunogenic profile in both small animal models and equine hosts, with strong antibody induction measured via indirect enzyme-linked immunosorbent assay (iELISA) and immunofluorescence assay [15]. The emphasis on VP2 is driven by its role as the primary target for neutralizing antibodies, making it an essential component in vaccine design and immunogenicity studies.

This platform is complemented by advances in reverse genetics, which have revolutionized the ability to manipulate the AHSV genome with precision. Techniques that allow directed genetic modifications enable researchers to selectively delete virulence factors or to swap genome segments encoding immunodominant proteins like VP2, thus laying the groundwork for the development of broadly protective multivalent vaccines. Replication-incompetent vaccine particles, with specific deficiencies engineered into critical proteins, have been generated to improve safety profiles while maintaining high immunogenicity. For instance, the assembly of defective AHSV particles by using a VP6-defective approach facilitates the creation of vaccine strains that are unable to replicate in vivo, thereby reducing the risk of reversion to virulence while promoting a strong host immune response [10].

The DISA-DIVA Approach and Multivalent Vaccine Development

Building on the reverse genetics platform, significant efforts have been directed toward the development of Disabled Infectious Single Animal (DISA)-DIVA vaccine strategies. These vaccines incorporate deliberate deletions, such as the removal of key sequences in the NS3/NS3a proteins, to restrict viral replication and enhance biosafety [24]. The DISA-DIVA platform has been extended to include all nine serotypes of AHSV, with a cocktail formulation eliciting serotype-specific neutralizing antibodies across the diverse viral landscape [52]. Evaluations in IFNAR (−/−) mouse models have provided compelling evidence that these multivalent vaccine candidates are not only safe but are capable of inducing broad cross-protection that may be extrapolated to equines. This strategy is crucial, especially in regions facing the threat of multiple serotype circulation, and is aligned with recommendations from organizations such as WOAH to maintain vigilant surveillance and rapid response capabilities.

Plant-Produced Virus-Like Particles and Recombinant Protein Vaccines

A complementary approach that has garnered considerable attention is the production of virus-like particles (VLPs) in plant expression systems. These VLPs mimic the native structure of AHSV without containing the viral genome, thereby offering an inherently safe alternative to live vaccines. Studies utilizing plant-produced chimaeric VLPs and soluble VP2 proteins have shown high immunogenicity in small animal models, such as IFNAR (−/−) mice, and have begun to translate into encouraging data in equine trials [21, 53]. The production process, based on Nicotiana benthamiana transient expression systems, represents a scalable and economically viable platform that can be deployed rapidly during outbreak scenarios, a quality highly valued by international agencies like the CDC and WHO when addressing emerging infectious threats.

One of the attractive features of these plant-based vaccines is their ability to induce both humoral and cell-mediated immune responses. This dual immunogenicity is critical for controlling an arboviral disease like African horse sickness, where early innate responses and long-term adaptive immunity need to synergize to prevent severe disease outcomes. Detailed studies have characterized the cytokine profiles and memory responses elicited by these vaccines, providing insights into their mechanism of action and long-term protective potential [7]. Additionally, the immunogenicity evaluations performed via serum neutralization tests and ELISA confirm that the quality and durability of the antibody response generated by these VLP constructs are comparable, if not superior, to those elicited by conventional platforms.

Modified Vaccinia Ankara (MVA)-Based Vaccines and Preformed Antigen Contributions

Another vector-based strategy that has shown promise employs modified vaccinia Ankara (MVA) viruses engineered to express AHSV antigens. Studies indicate that MVA-VP2 vaccines deliver a dual mechanism of antigen presentation, through both the expression of de novo synthesized VP2 in infected cells and the presence of preformed VP2 contained in the inoculum [54]. Preformed antigen availability appears to be a significant correlate of protection, correlating strongly with virus neutralization titers and the rapid onset of protective immunity in murine models. This finding suggests that vaccine dosing and purification methods, which influence the amount of preformed VP2, critically affect immunogenic outcomes. As such, precise formulation protocols are necessary to maximize the protective efficacy of these recombinant vaccines.

Integration of DIVA Strategies and Field Diagnostics

Innovations in vaccine design are not solely focused on inducing protective immunity; they are also accompanied by the development of robust diagnostic tools for differentiating vaccinated animals from those infected naturally, a need highlighted by the WOAH in recently affected countries. The integration of DIVA strategies into vaccine platforms, particularly with DISA constructs, facilitates the use of novel diagnostic assays such as real-time RT-PCR methods specifically modified to detect field strains versus vaccine strains [22, 39]. This capability is of paramount importance for maintaining disease-free status in regions with rigorous animal health monitoring programs, such as those recommended by the CDC and FAO, and supports effective outbreak control and surveillance measures.

Immunogenicity Evaluations and Preclinical Models

Thorough assessments of vaccine-induced immune responses form the cornerstone of these advances. In-depth preclinical evaluations in murine systems and experimental infections in horses have provided comprehensive profiles of both humoral and cell-mediated immunity. Studies involving passive transfer of anti-AHSV serum have further illustrated the protective role of neutralizing antibodies, underscoring the potential for sero-therapeutic applications [55]. Immunogenicity evaluations typically include virus neutralization assays, ELISA, and advanced transcriptomic analyses, each contributing to a better understanding of the host-pathogen interaction and the durability of vaccine-induced protection. These detailed immunological assessments not only validate the efficacy of novel vaccine candidates but also guide iterative improvements in vaccine design.

Collectively, these advancements reflect a multi-pronged approach to combating African horse sickness virus. By harnessing state-of-the-art molecular techniques, reverse genetics, vector-based systems, and plant biotechnology, researchers are establishing a solid foundation for safer, more effective, and broadly protective vaccine candidates. This integrated strategy supports the global commitment to controlling zoonotic and economically impactful livestock diseases as endorsed by international health organizations.

Experimental Models and Future Directions in African Horse Sickness Virus Research

The development of robust experimental models has been pivotal in understanding the pathogenesis, host immune response, and viral biology of African horse sickness virus (AHSV). A variety of in vivo and in vitro systems have been employed to delineate the molecular mechanisms driving viral replication, virulence, and transmission dynamics. In particular, small animal models such as IFNAR (–/–) mice have been instrumental in replicating many features of equine infection while offering a less logistically demanding platform compared to equine studies [28, 31, 58]. These models have enabled in-depth investigations into cytokine mRNA expression profiles, tissue-specific pathology, and host–virus interactions that underlie the lethal outcomes observed in naïve equine populations.

Animal Models and Their Contributions

IFNAR (–/–) mice have been established as one of the most reliable surrogate hosts for AHSV studies, mirroring many aspects of equine disease progression such as disseminated intravascular coagulation, endothelial damage, and overt inflammatory responses [28, 31]. Detailed examinations in these models have not only elucidated innate immune signaling pathways but also refined our understanding of the balance between protective immunity and viral immune evasion. Experimental infections in horses, despite their higher logistical and ethical constraints, have provided invaluable insights, particularly regarding the coagulopathy and hemorrhagic manifestations associated with AHSV infection [29, 57]. Moreover, emerging data also underscore the complexity of host range, as sero-epidemiological surveys in non-equid species such as dogs hint at potential interspecies contacts that could influence viral ecology [37]. These models, endorsed and referenced in guidelines by international organizations such as the WOAH, remain critical for studies aimed at curbing the economic impact of AHSV outbreaks, which are of interest to agencies like the CDC, WHO, and FAO.

In Vitro and Molecular Models: Advancing Mechanistic Insights

In vitro experimental systems, including primary cell cultures and specialized insect-derived cells, have provided the necessary platforms for dissecting the replication cycle and host cellular interactions of AHSV. Advanced molecular assays, including multiplex PCR methods [4] and innovative nucleic acid detection platforms such as RT-MIRA [16], have greatly refined the diagnostic capabilities, enabling rapid and sensitive detection of viral RNA even at low copy numbers. These assays are particularly valuable as field-deployable tools, which complement the stringent surveillance protocols recommended by organizations like the WOAH.

Moreover, research focusing on viral protein function has leveraged reverse genetics systems. These systems have been used to manipulate AHSV genomes and investigate the roles of various structural and non-structural proteins. For example, studies targeting the VP7 core protein have clarified its involvement in particle assembly and potential interactions with insect vectors, a finding that may aid in the rational design of vaccines that interrupt the viral transmission cycle [2, 3]. The discovery of novel epitopes on VP7 and other antigens through state-of-the-art mapping techniques [3, 56] guides the development of next-generation serological assays and vaccines that can be tailored for different serotypes.

Advances in Diagnostic Tools and Molecular Techniques

The evolution of diagnostic methodologies has paralleled vaccine development and vector management strategies. Improved RT-PCR protocols, including modifications in primer design to capture emerging variants [22, 47], are setting new standards for sensitivity and specificity. Nanopore sequencing has emerged as a rapid method to analyze the complete viral genome during outbreak investigations, such as during the recent outbreak in Thailand [20]. This high-resolution approach not only facilitates epidemiological tracing but also aids in monitoring viral evolution, which is crucial in regions where vaccination is coupled with stringent movement controls as recommended by international guidelines (WOAH, WHO).

FTA cards and loop-mediated isothermal amplification (LAMP) assays further promise to revolutionize how field samples are handled, stored, and processed, thereby enhancing the reliability of molecular diagnostics even in resource-limited or remote settings [48, 60]. These advances are ensuring that rapid detection and differentiation of vector-borne viruses, including AHSV, become cornerstone practices in outbreak preparedness and control.

Vaccine Development and Reverse Genetics Approaches

One of the most dynamic arenas in AHSV research is the development of safer and more efficacious vaccines. Owing to the high risk associated with live attenuated vaccines, including potential reassortment events and residual virulence, novel strategies are being pursued utilizing recombinant platforms and reverse genetics. The design of recombinant viral vaccines, such as those based on modified Vaccinia Ankara (MVA) expressing VP2 antigens [54, 55], has shown great promise in experimental models by inducing robust neutralizing antibody responses. Parallel studies using plant-produced virus-like particles (VLPs) have underscored the potential for scalable, cost-effective vaccine production platforms with excellent safety profiles [53, 59].

The advent of Disabled Infectious Single Animal (DISA) vaccines is particularly noteworthy. By engineering viruses that are replication-abortive yet immunogenic, researchers have crafted multivalent vaccine formulations that target all nine AHSV serotypes [12, 24, 52]. Reverse genetics systems not only enable the precise deletion of virulence factors like NS3 and NS4, but they also permit the exchange of serotype-determining segments such as VP2, paving the way to tailor vaccines based on locally circulating strains [9, 10]. Such innovations are essential given the economic and trade implications of AHSV outbreaks, which are of critical concern to organizations like the WOAH and FAO.

Future Directions in AHSV Research

Looking ahead, research on AHSV is poised to benefit from an integrated approach that harnesses advanced genetic tools, computational modeling, and innovative in vivo systems. Continued refinement of reverse genetics techniques will facilitate the creation of designer vaccine strains that are both DIVA-compatible and able to elicit cross-protective immunity. Harnessing next-generation sequencing technologies to monitor viral evolution in real time will be crucial in adapting vaccine strategies to emerging variants.

Moreover, ecological niche modeling and spatio-temporal analyses [36, 38, 45, 46] promise to enhance our ability to predict and manage outbreaks by identifying regions particularly suited for AHSV transmission based on climatic and environmental variables. These models will serve as essential tools for risk-based surveillance, enabling targeted interventions that minimize both the public health and economic impacts of potential outbreaks.

In conclusion, the synergy between experimental animal models, molecular diagnostic innovations, and advanced reverse genetics is charting a promising course toward the comprehensive control of African horse sickness virus. Researchers continue to build on these platforms to not only decipher the intricacies of viral pathogenesis but also to forge new avenues for vaccines and diagnostic tools that align with global standards set forth by the CDC, WHO, and WOAH.

References

[1] Zhang M, Wang X, Guo S, Wang L, Fu B, Wang J, et al.. Identification and Genetic Characterization of a Strain of African Horse Sickness Virus Serotype 1 and Its Safety Evaluation in a Mouse Model. Microorganisms. 2025. DOI: https://doi.org/10.3390/microorganisms13102314

[2] Buyens ARM, Staden Vv, Theron J. The VP7 protein of the African horse sickness virus core particle facilitates binding to Culicoides sonorensis cells in an RGD-independent manner.. Virology. 2025. DOI: https://doi.org/10.1016/j.virol.2025.110694

[3] Hu X, Xu J, Wang X, Tian Z, Guan G, Luo J, et al.. Identification of three novel linear B-cell epitopes on VP7 of African horse sickness virus using monoclonal antibodies.. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110258

[4] Villalba R, Tena-Tomás C, Ruano MJ, Valero-Lorenzo M, López-Herranz A, Cano-Gómez C, et al.. Development and Validation of Three Triplex Real-Time RT-PCR Assays for Typing African Horse Sickness Virus: Utility for Disease Control and Other Laboratory Applications. Viruses. 2024. DOI: https://doi.org/10.3390/v16030470

[5] Maurer L, Paslaru A, Torgerson P, Veronesi E, Mathis A. Vector competence of Culicoides biting midges from Switzerland for African horse sickness virus and epizootic haemorrhagic disease virus.. Schweizer Archiv für Tierheilkunde. 2022. DOI: https://doi.org/10.17236/sat00337

[6] Odend'hal S. African horse sickness virus. CABI Compendium. 2022. DOI: https://doi.org/10.1016/B978-0-12-524180-9.50010-8

[7] Fearon SH, Dennis SJ, Hitzeroth I, Rybicki E, Meyers A. Humoral and cell-mediated immune responses to plant-produced African horse sickness virus VP7 quasi-crystals.. Virus Research. 2021. DOI: https://doi.org/10.1016/j.virusres.2020.198284

[8] Ngoveni H, Schalkwyk Av, Koekemoer J. Evidence of Intragenic Recombination in African Horse Sickness Virus. Viruses. 2019. DOI: https://doi.org/10.3390/v11070654

[9] Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design. Current Opinion in Virology. 2020. DOI: https://doi.org/10.1016/j.coviro.2020.06.003

[10] Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes. Journal of Virology. 2016. DOI: https://doi.org/10.1128/JVI.00548-16

[11] Rijn PVv, Water SVDvd, Feenstra F, Gennip RGv. Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV). Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0574-7

[12] Water SVDvd, Gennip RGv, Potgieter CA, Wright I, Rijn PVv. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV. Journal of Virology. 2015. DOI: https://doi.org/10.1128/JVI.01052-15

[13] Conradie AM, Stassen L, Huismans H, Potgieter CA, Theron J. Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus. Virology. 2016. DOI: https://doi.org/10.1016/j.virol.2016.07.010

[14] Potgieter AC, Wright I, Dijk AAv. Consensus Sequence of 27 African Horse Sickness Virus Genomes from Viruses Collected over a 76-Year Period (1933 to 2009). Genome Announcements. 2015. DOI: https://doi.org/10.1128/genomeA.00921-15

[15] Ma X, Zhang M, Zhang X, Qi T, Zhang W, Zhao Y, et al.. Construction and Immunogenicity Evaluation of a Recombinant Fowlpox Virus Expressing VP2 Gene of African Horse Sickness Virus Serotype 1. Microorganisms. 2025. DOI: https://doi.org/10.3390/microorganisms13122807

[16] Huang C, Wang J, Ruan Z, Wu J, Lin Y, Cao C, et al.. Real-Time Reverse Transcription Multienzyme Isothermal Rapid Amplification for Rapid Detection of African Horse Sickness Virus. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/1852368

[17] Bunpapong N, Charoenkul K, Nasamran C, Chamsai E, Udom K, Boonyapisitsopa S, et al.. African Horse Sickness Virus Serotype 1 on Horse Farm, Thailand, 2020. Emerging Infectious Diseases. 2021. DOI: https://doi.org/10.3201/eid2708.210004

[18] Bekker S, Huismans H, Staden Vv. Generation of a Soluble African Horse Sickness Virus VP7 Protein Capable of Forming Core-like Particles. Viruses. 2022. DOI: https://doi.org/10.3390/v14081624

[19] Bekker S, Potgieter CA, Staden Vv, Theron J. Investigating the Role of African Horse Sickness Virus VP7 Protein Crystalline Particles on Virus Replication and Release. Viruses. 2022. DOI: https://doi.org/10.3390/v14102193

[20] Xinyu T, Yifan W, Rajapakse MP, Lee B, Songkasupa T, Suwankitwat N, et al.. Use of Nanopore Sequencing to Characterize African Horse Sickness Virus (AHSV) from the African Horse Sickness Outbreak in Thailand in 2020.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14056

[21] O’Kennedy M, Coetzee P, Koekemoer O, Plessis LDd, Lourens CW, Kwezi L, et al.. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice.. Vaccine. 2022. DOI: https://doi.org/10.1016/j.vaccine.2022.06.079

[22] Penzhorn L, Crafford JE, Guthrie A. Enhancing African horse sickness virus detection: comparing and adapting PCR assays. Journal of Veterinary Diagnostic Investigation. 2026. DOI: https://doi.org/10.1177/10406387261417355

[23] Wall GV, Wright I, Barnardo C, Erasmus B, Staden Vv, Potgieter AC. African horse sickness virus NS4 protein is an important virulence factor and interferes with JAK-STAT signaling during viral infection.. Virus Research. 2021. DOI: https://doi.org/10.1016/j.virusres.2021.198407

[24] Rijn PVv, Maris-Veldhuis M, Potgieter CA, Gennip RGv. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.. Vaccine. 2018. DOI: https://doi.org/10.1016/j.vaccine.2018.03.003

[25] Zwart L, Potgieter CA, Clift S, Staden Vv. Characterising Non-Structural Protein NS4 of African Horse Sickness Virus. PLoS ONE. 2015. DOI: https://doi.org/10.1371/journal.pone.0124281

[26] Ferreira-Venter L, Venter E, Theron J, Staden Vv. Targeted mutational analysis to unravel the complexity of African horse sickness virus NS3 function in mammalian cells.. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2019.03.005

[27] Sánchez-Matamoros A, Beck C, Kukielka D, Lecollinet S, Blaise-Boisseau S, Garnier A, et al.. Development of a Microsphere-based Immunoassay for Serological Detection of African Horse Sickness Virus and Comparison with Other Diagnostic Techniques.. Transboundary and Emerging Diseases. 2016. DOI: https://doi.org/10.1111/tbed.12340

[28] Calvo-Pinilla E, Jiménez-Cabello L, Utrilla-Trigo S, Illescas-Amo M, Ortego J. Cytokine mRNA Expression Profile in Target Organs of IFNAR (-/-) Mice Infected with African Horse Sickness Virus. International Journal of Molecular Sciences. 2024. DOI: https://doi.org/10.3390/ijms25042065

[29] Schliewert E, Goddard A, Hooijberg E. Experimental infection of horses with African horse sickness virus results in overt disseminated intravascular coagulation. Equine Veterinary Journal. 2026. DOI: https://doi.org/10.1002/evj.70134

[30] Pipitpornsirikul P, Thangthamniyom N, Laikul A, Songkasupa T, Pathomsakulwong W, Apichaimongkonkun T, et al.. The Viremic Phase and Humoral Immune Response Against African Horse Sickness Virus That Emerged in Thailand in 2020. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12090878

[31] Jones LM, Hawes PC, Salguero F, Castillo-Olivares J. Pathological features of African horse sickness virus infection in IFNAR−/− mice. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1114240

[32] Faber E, Tshilwane SI, Kleef M, Pretorius A. Virulent African horse sickness virus serotype 4 interferes with the innate immune response in horse peripheral blood mononuclear cells in vitro.. Infection, Genetics and Evolution. 2021. DOI: https://doi.org/10.1016/j.meegid.2021.104836

[33] Faber E, Tshilwane SI, Kleef MV, Pretorius A. Apoptosis versus survival of African horse sickness virus serotype 4-infected horse peripheral blood mononuclear cells.. Virus Research. 2021. DOI: https://doi.org/10.1016/j.virusres.2021.198609

[34] Rijn PA. African Horse Sickness Virus (Reoviridae). . 2019. DOI: https://doi.org/10.1016/B978-0-12-809633-8.20937-0

[35] Chinyere CN, Ajaebili AC, Peter-Ajuzie IK, Galadima HB, Daodu O, Fatola O, et al.. Prevalence of African Horse Sickness Virus Antibodies in Horses and Selected Wildlife in Four Geographical Regions of Nigeria. Veterinary Medicine International. 2025. DOI: https://doi.org/10.1155/vmi/4106678

[36] Assefa A, Tibebu A, Bihon A, Dagnachew A, Muktar Y. Ecological niche modeling predicting the potential distribution of African horse sickness virus from 2020 to 2060. Scientific Reports. 2022. DOI: https://doi.org/10.1038/s41598-022-05826-3

[37] Hanekom J, Lubisi B, Leisewitz A, Guthrie A, Fosgate G. The seroprevalence of African horse sickness virus, and risk factors to exposure, in domestic dogs in Tshwane, South Africa.. Preventive Veterinary Medicine. 2023. DOI: https://doi.org/10.1016/j.prevetmed.2023.105868

[38] Fairbanks EL, Baylis M, Daly J, Tildesley M. Inference for a spatio-temporal model with partial spatial data: African horse sickness virus in Morocco.. Epidemics. 2022. DOI: https://doi.org/10.1016/j.epidem.2022.100566

[39] Wang Y, Ong J, Ng O, Songkasupa T, Koh E, Wong J, et al.. Development of Differentiating Infected from Vaccinated Animals (DIVA) Real-Time PCR for African Horse Sickness Virus Serotype 1. Emerging Infectious Diseases. 2022. DOI: https://doi.org/10.3201/eid2812.220594

[40] Grewar J, Kotze J, Parker BJ, Helden Lv, Weyer C. An entry risk assessment of African horse sickness virus into the controlled area of South Africa through the legal movement of equids. PLoS ONE. 2021. DOI: https://doi.org/10.1371/journal.pone.0252117

[41] Riddin M, Venter G, Labuschagne K, Villet M. Culicoides species as potential vectors of African horse sickness virus in the southern regions of South Africa. Medical and Veterinary Entomology. 2019. DOI: https://doi.org/10.1111/mve.12391

[42] Oura C. A possible role for domestic dogs in the spread of African horse sickness virus. The Veterinary Record. 2018. DOI: https://doi.org/10.1136/vr.k2641

[43] Fall M, Diarra M, Fall A, Balenghien T, Seck M, Bouyer J, et al.. Culicoides (Diptera: Ceratopogonidae) midges, the vectors of African horse sickness virus – a host/vector contact study in the Niayes area of Senegal. Parasites & Vectors. 2015. DOI: https://doi.org/10.1186/s13071-014-0624-1

[44] Karamalla ST, Gubran AI, Adam I, Abdalla TM, Sinada RO, Haroun EM, et al.. Sero-epidemioloical survey on African horse sickness virus among horses in Khartoum State, Central Sudan. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1554-5

[45] Assefa A, Tibebu A, Bihon A, Dagnachew A, Muktar Y. Ecological Niche Modeling Predicting the Potential Distribution of African Horse Sickness Virus from 2020 - 2060. . 2021. DOI: https://doi.org/10.21203/rs.3.rs-811989/v1

[46] Sánchez-Matamoros A, Sánchez-Vizcaíno J, Rodríguez-Prieto V, Iglesias E, Martínez-López B, Martínez-López B. Identification of Suitable Areas for African Horse Sickness Virus Infections in Spanish Equine Populations.. Transboundary and Emerging Diseases. 2016. DOI: https://doi.org/10.1111/tbed.12302

[47] Morales J, Ruano MJ, Tena-Tomás C, Schalkwyk Av, Loundras E, Valero-Lorenzo M, et al.. Modification and Validation of a Reference Real-Time RT-PCR Method for the Detection of a New African Horse Sickness Virus Variant. bioRxiv. 2025. DOI: https://doi.org/10.3390/microorganisms13122684

[48] Taesuji M, Rattanamas K, Yim PB, Ruenphet S. Stability and Detection Limit of Avian Influenza, Newcastle Disease Virus, and African Horse Sickness Virus on Flinders Technology Associates Card by Conventional Polymerase Chain Reaction. Animals. 2024. DOI: https://doi.org/10.3390/ani14081242

[49] Langlands Z, Gubbins S, Carpenter S, England M. Culicoides biting midges (Diptera: Ceratopogonidae) feeding on donkeys in the United Kingdom, with reference to the risk of transmission and persistence of African horse sickness virus.. Medical and Veterinary Entomology. 2026. DOI: https://doi.org/10.1111/mve.70061

[50] Ashby M, Moore R, King S, Newbrook K, Flannery J, Batten C. Designing a Multiplex PCR-xMAP Assay for the Detection and Differentiation of African Horse Sickness Virus, Serotypes 1–9. Microorganisms. 2024. DOI: https://doi.org/10.3390/microorganisms12050932

[51] Rattanamas K, Taesuji M, Kulthonggate U, Jantafong T, Mamom T, Ruenphet S. Sensitivity of RNA viral nucleic acid-based detection of avian influenza virus, Newcastle disease virus, and African horse sickness virus on flinders technology associates card using conventional reverse-transcription polymerase chain reaction. Veterinary World. 2022. DOI: https://doi.org/10.14202/vetworld.2022.2754-2759

[52] Utrilla-Trigo S, Jiménez-Cabello L, Gennip RGv, Rijn PAv, Ortego J, Calvo-Pinilla E. Multivalent Disabled Infectious Single Animal (DISA)-DIVA vaccine for all nine serotypes of African horse sickness virus (AHSV) is broadly protective in IFNAR (-/-) mice. Veterinary Research. 2026. DOI: https://doi.org/10.1186/s13567-026-01753-7

[53] Dennis SJ, O’Kennedy M, Rutkowska D, Tsekoa T, Lourens CW, Hitzeroth I, et al.. Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses. Veterinary Research. 2018. DOI: https://doi.org/10.1186/s13567-018-0600-4

[54] Calvo-Pinilla E, Gubbins S, Mertens P, Ortego J, Castillo-Olivares J. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. Antiviral Research. 2018. DOI: https://doi.org/10.1016/j.antiviral.2018.04.015

[55] Calvo-Pinilla E, Poza Fdl, Gubbins S, Mertens P, Ortego J, Castillo-Olivares J. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge. Antiviral Research. 2015. DOI: https://doi.org/10.1016/j.antiviral.2015.01.009

[56] Faber E, Schalkwyk Av, Tshilwane SI, Kleef MV, Pretorius A. Identification of T cell and linear B cell epitopes on African horse sickness virus serotype 4 proteins VP1-1, VP2, VP4, VP7 and NS3.. Vaccine. 2023. DOI: https://doi.org/10.1016/j.vaccine.2023.12.028

[57] Schliewert E, Hooijberg E, Steyn JS, Potgieter CA, Fosgate G, Goddard A. Experimental infection with African Horse Sickness Virus in horses induces only mild temporal hematologic changes and acute phase reactant response.. American Journal of Veterinary Research. 2022. DOI: https://doi.org/10.2460/ajvr.22.08.0123

[58] Durán-Ferrer M, Villalba R, Fernández-Pacheco P, Tena-Tomás C, Jiménez-Clavero MÁ, Bouzada J, et al.. Clinical, Virological and Immunological Responses after Experimental Infection with African Horse Sickness Virus Serotype 9 in Immunologically Naïve and Vaccinated Horses. Viruses. 2022. DOI: https://doi.org/10.3390/v14071545

[59] Dennis SJ, Meyers A, Guthrie A, Hitzeroth I, Rybicki E. Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine. Plant Biotechnology Journal. 2017. DOI: https://doi.org/10.1111/pbi.12783

[60] Fowler V, Howson E, Flannery J, Romito M, Lubisi A, Agüero M, et al.. Development of a Novel Reverse Transcription Loop‐Mediated Isothermal Amplification Assay for the Rapid Detection of African Horse Sickness Virus. Transboundary and Emerging Diseases. 2016. DOI: https://doi.org/10.1111/tbed.12549